AstraZeneca Announces £11bn China Investment After Scaling Back UK Expansion Plans
British pharmaceutical group pledges $15bn in Chinese manufacturing, research and development as part of deeper global strategy amid shifting domestic priorities
AstraZeneca, the United Kingdom’s largest pharmaceutical company, has unveiled a significant investment plan committing up to fifteen billion dollars — equivalent to around £11 billion — in China through to 2030, in a move that follows the company’s decision to shelve major expansion plans in Britain.
The investment, announced during British Prime Minister Sir Keir Starmer’s visit to Beijing, will focus on expanding medicines manufacturing, establishing research and development hubs and strengthening partnerships within China’s rapidly evolving life sciences ecosystem.
This commitment includes the previously announced two and a half billion dollar research hub in Beijing, as well as new manufacturing capacity across cities including Wuxi, Taizhou, Qingdao and additional sites that will serve both domestic and international markets.
AstraZeneca’s chief executive, Pascal Soriot, described the pledge as a “landmark investment” and the start of an “exciting next chapter” for the company in China, where it already operates multiple research centres and has deep collaboration with more than five hundred clinical hospitals.
At the same time, the company’s strategic pivot comes amid tensions with the UK government over drug pricing and industrial policy, which contributed to AstraZeneca pausing a planned two hundred million pound research expansion in Cambridge and abandoning a four hundred and fifty million pound project at its vaccine site in Speke near Liverpool.
Sir Keir Starmer welcomed the investment as beneficial for AstraZeneca’s growth and supportive of thousands of UK jobs, noting that partnerships between British universities and Chinese research institutions could further enhance the UK’s life sciences sector.
The plan is also set against a backdrop of robust global operations for AstraZeneca, which has recently pursued acquisitions including Gracell Biotechnologies to bolster its oncology capabilities and is concurrently expanding in other key markets including the United States.
While AstraZeneca faces regulatory inquiries in China relating to allegations of unpaid import taxes and other compliance matters, the company emphasised its commitment to the Chinese market as central to its innovation and manufacturing strategy.
By broadening its footprint in China, AstraZeneca aims to accelerate its development of breakthrough therapies including cell therapies and radioconjugates, while reinforcing international production networks that support global public health objectives.
The investment, announced during British Prime Minister Sir Keir Starmer’s visit to Beijing, will focus on expanding medicines manufacturing, establishing research and development hubs and strengthening partnerships within China’s rapidly evolving life sciences ecosystem.
This commitment includes the previously announced two and a half billion dollar research hub in Beijing, as well as new manufacturing capacity across cities including Wuxi, Taizhou, Qingdao and additional sites that will serve both domestic and international markets.
AstraZeneca’s chief executive, Pascal Soriot, described the pledge as a “landmark investment” and the start of an “exciting next chapter” for the company in China, where it already operates multiple research centres and has deep collaboration with more than five hundred clinical hospitals.
At the same time, the company’s strategic pivot comes amid tensions with the UK government over drug pricing and industrial policy, which contributed to AstraZeneca pausing a planned two hundred million pound research expansion in Cambridge and abandoning a four hundred and fifty million pound project at its vaccine site in Speke near Liverpool.
Sir Keir Starmer welcomed the investment as beneficial for AstraZeneca’s growth and supportive of thousands of UK jobs, noting that partnerships between British universities and Chinese research institutions could further enhance the UK’s life sciences sector.
The plan is also set against a backdrop of robust global operations for AstraZeneca, which has recently pursued acquisitions including Gracell Biotechnologies to bolster its oncology capabilities and is concurrently expanding in other key markets including the United States.
While AstraZeneca faces regulatory inquiries in China relating to allegations of unpaid import taxes and other compliance matters, the company emphasised its commitment to the Chinese market as central to its innovation and manufacturing strategy.
By broadening its footprint in China, AstraZeneca aims to accelerate its development of breakthrough therapies including cell therapies and radioconjugates, while reinforcing international production networks that support global public health objectives.
